Therapeutic angiogenesis provides a potential alternative for the treatment of cardiovascular ischemic diseases. Vascular endothelial growth factor (VEGF) is an important component of the angiogenic response to ischemia. Here we used adeno-associated virus (AAV) gene delivery to skeletal muscle to examine the effects of VEGF vs. a stabilized form of hypoxia-inducible factor-1α (HIF-1α). The recombinant AAVs were injected into mouse tibialis anterior muscle, and their effects were analyzed by immunohistochemistry and functional assays. These analyses showed that stabilized HIF-1α markedly increase capillary sprouting and proliferation, whereas VEGF 164 or VEGF 120 induced only proliferation of endothelial cells without formation of proper capillary structures. The Evans Blue permeability assay indicated that, unlike VEGF, HIF-1α overexpression did not increase vascular leakiness in the transduced muscle. Doppler ultrasound imaging showed that vascular perfusion in the HIF-1α treated muscles was significantly enhanced when compared to the controls and not further improved by co-expression of the arteriogenic growth factors angiopoietin-1 or platelet-derived growth factor-B. Our results show that AAV-mediated transduction of a stabilized form of HIF-1α can circumvent the problems associated with overexpression of individual angiogenic growth factors. HIF-1α should thus offer a potent alternative for pro-angiogenic gene therapy.
today the best-characterized angiogenic growth factor (1) . VEGF exerts its effects by stimulating the proliferation and migration of endothelial cells. In addition, VEGF is a strong inducer of vascular permeability (2) . Gene targeting studies have demonstrated the critical importance of VEGF for both vasculogenesis and angiogenesis, as heterozygous gene dosage is incompatible with normal embryonic development (3, 4) . As a result, VEGF has been used in numerous preclinical and early clinical gene or protein therapy trials with varying success (5) . However, more recently, it has been observed that VEGF is not sufficient as a single agent to create the complex structures required for a functional vasculature, thereby challenging the early trials. As an example, VEGF-induced vessels are often leaky and do not properly connect to the existing vasculature (6) . To facilitate arteriogenesis required for collateral formation, some studies have used additional growth factors, such as angiopoietin-1 (Ang-1) together with VEGF, and obtained reduced leakiness in the newly formed vessels (7) .
In the present study, we wanted to study whether a species-matched VEGF is required for optimal angiogenesis and to compare vessels induced by overexpression of a stabilized hypoxiainducible factor-1α (HIF-1α) vs. VEGF. Furthermore, we studied the effects of growth factor combinations on the production of a functional neo-vasculature. We used recombinant HIF-1α, which is stabilized by point-mutations to decrease its normal proteolytic degradation under normoxic conditions (8) . HIF-1α is a well-known regulator of several genes whose function is induced by hypoxia such as VEGF (9) (10) (11) (12) . As the gene transfer vehicle, we used adenoassociated virus (AAV) because of its optimal transduction profile for muscle-directed gene therapy and lack of inflammatory responses (13) .
MATERIALS AND METHODS

Production of recombinant AAV vectors and analysis of their in vitro expression
The coding regions of the full-length or C-terminally truncated and VP16 replaced mouse HIF-1α mutant (P402A/P563A, see Results), human Ang-1, and human platelet-derived growth factor-B (PDGF-B) were cloned into the psub-CMV-WPRE AAV2 expression vector (14, 15) . The cDNAs encoding VEGF-A 120 and VEGF-A 164 (a kind gift of Christer Betsholtz) were cloned into the psub-CAG-WPRE vector, which contains a composite CMV promoter-chicken ß-actin enhancer element (16) . The rAAVs were produced with the two-plasmid transfection method as described (17) . The titers of the recombinant AAVs were 5 × 10 11 -10 12 gp/ml. The expression of the recombinant proteins was verified by transducing HeLa cells with the rAAVs. The nuclear expression of mHIF-1α was determined by immunofluorescence staining with anti-HIF-1α antibodies (Abcam). The expression of VEGF 120 , VEGF 164 , Ang-1, and PDGF-B was analyzed by co-precipitation with the respective receptor-Ig molecules (VEGFR-1-Ig, Tie2-Ig, PDGFR-β-Ig), and the resultant protein complexes were separated in SDS-PAGE.
Expression of recombinant factor-AAVs in vivo and immunohistological analyses
FVB mice (5-6 weeks old) were anesthesized with Rompun (Bayer)-Ketalar (Pfizer). The undiluted rAAV preparations (25 μl; 1.5-2.5×10 10 gp) were injected into the tibialis anterior (TA) muscles, and the effects were analyzed by immunohistochemistry 4-8 weeks later. In all experiments, human serum albumin (HSA)-AAV was used as a control, and enhanced green fluorescent protein (EGFP)-AAV was used to localize expression. For the analyses, the injected muscles were dissected and frozen in TissueTek (Sakura Finetek). Cryosections (8 μm) were cut, fixed with acetone, and subjected to immunostaining with the following antibodies: rat anti-PECAM-1 (PharMingen), rat anti-CD45 (PharMingen), rat F4-80 (Serotec), rabbit antiphosphohistone H3 (pHH3, Upstate), rat anti-NG2 (Chemicon), or mouse anti-smooth muscle actin-Cy3 (SMA, Sigma). The unconjugated primary antibodies were detected with Alexa Fluor conjugated secondary antibodies (Molecular Probes, Eugene, OR). For analysis of thick sections, deep-anesthesized mice were perfusion-fixed through the left ventricle with 1% PFA. TA muscles were dissected and 100 μm cryosections cut. The sections were post-fixed with acetone and stainings were processed as above.
Evans Blue permeability assay
Mouse TA muscles were injected with the rAAVs under study, and gene expression was allowed to continue for 8 weeks. Subsequently, the mice were anesthesized and 300 μl of 1% Evans Blue-PBS was injected into the tail vein. The dye was allowed to circulate for 30 min, after which the mice were killed and TA muscles dissected. The extravasated dye was released by incubating the muscles in formamide at +55°C o/n and quantitated by spectrophotometer at A620 nm.
In vivo ultrasound measurement of perfusion in transduced muscles
TA muscles were injected as above and expression continued for 8 weeks. The mice were anesthesized, and perfusion in TA muscles was measured with an Acuson Sequoia 512 ultrasound apparatus (Acuson, Mountain View, CA). Intensities of the ultrasound signals were analyzed with the Data Pro 2.13 (Noesis SA, Courtaboeuf, Cedex, France) program. Statistical analysis was carried out using Student's t-test.
In vivo imaging of luciferase expression
rAAV-Luciferase transduced mice were anesthesized and D-luciferin (Synchem, Kassel, Germany) was injected i.p. (150 mg/kg). After 10 min the mice were imaged with the IVIS system (Xenogen, Alameda, CA).
RESULTS
To study the effects of different factors on angiogenesis in mouse skeletal muscle, the cDNAs of interest were cloned into an AAV-2 vector under the control of a CMV or CAG promoter (Fig.  1A) . The tested constructs included mutated mHIF-1α-VP16, where the C-terminal transcription activation domain (TAD) is replaced with the VP16 viral TAD and mHIF-1α-FL, which encodes the full-length mouse HIF-1α. Both constructs were stabilized against prolyl hydroxylation and subsequent ubiquitin-mediated proteolytic degradation by point mutations (P402A/P563A; Fig.  1B ) (8) . VEGF 164 , VEGF 120 , Ang1 and PDGF-B protein production by the rAAV-transduced HeLa cells was confirmed in vitro by receptor binding assays (Fig. 1C) . The mutated HIF-1α constructs were tested by immunofluorescence. As expected, the stabilized mHIF-1α full-ength (FL) and mHIF-1α-VP16 recombinant proteins were located in the nucleae of the transduced HeLa cells even in normoxic conditions ( Fig. 1D and data not shown).
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In vivo expression analysis of recombinant mHIF-1α constructs stabilized against proteolytic degradation Vectors were injected intramuscularly into mouse TA muscles. To be able to localize the transduced myotubes, rAAV-luciferase was coinjected with the test vectors. As controls, the contralateral TAs were injected with rAAV-luciferase together with rAAVs expressing human serum albumin (HSA). The injected mice were imaged at one-week intervals starting one week after injection. Typically for the rAAV expression profile, luciferase expression in the control mTAs was low at one week and gradually increased thereafter to reach maximal levels at 3 weeks. The stabilized mHIF-1α FL transduced TA followed an expression profile mimicking the control muscle. However, luciferase expression in the rAAV-mHIF-1α-VP16 coinjected mTA had started to decline by 2 weeks and continued declining, until at 5 weeks expression was no longer detected (Fig. 2) . This phenomenon was verified in several mice injected with rAAVmHIF-1α-VP16 in an identical setup. As mHIF-1α-VP16 appeared unsuitable for further studies, we used the mHIF-1α FL construct for all subsequent experiments.
Angiogenic response to mHIF-1α vs. VEGF in mouse tibialis anterior muscle
The rAAVs encoding mHIF-1α, VEGF 120 , or VEGF 164 were injected into TA muscles. Due to the gradual increase of rAAV transgene expression in vivo (18) , the muscles were dissected at 4-5 weeks post-transduction and analyzed by immunohistochemistry. Capillary outgrowth was verified by staining for the PECAM-1 cell surface marker on endothelial cells and for phosphohistone H3 (pHH3) for proliferating cells. Mural cell proliferation, depicting the maturation of de novo capillaries, was visualized by staining for the proteoglycan NG2 in pericytes and smooth-muscle actin (SMA) in smooth muscle cells. The analyses showed striking differences in the responses induced by the VEGF isoforms or by mHIF-1α. As shown by staining for PECAM-1, NG2, and pHH3, both VEGF isoforms triggered massive proliferation of capillary endothelial cells, but without proper formation of new capillaries per se (Fig. 3C, D, H) . The high activity of mouse VEGFs in mouse tissues was evident when compared with the effects obtained with human VEGF, which showed remarkably more subdued effects in an identical experimental set up (data not shown). In contrast to the results obtained with mouse VEGF overexpression, well-demarcated sprouting capillaries proliferated in muscles expressing mHIF-1α (Fig. 3B, G) . Increased numbers of NG2 positive pericytes were seen in both VEGF and mHIF-1α transduced muscles, but only the latter had pericytes organized in a sprouting capillary-like pattern (Fig. 3B, C, D ; arrows in Fig. 4F, G 
, H).
Both mHIF-1α and VEGF recruited leukocytes to the sites of AAV gene expression. These cells expressed the common leukocyte antigen CD45, and most of the cells were also positive for the macrophage marker F4-80 (Fig. 3A -D, insets and data not shown). This is in agreement with the previously described chemotactic properties of VEGF toward VEGF receptor-1 expressing monocytes and macrophages (19) . Muscles transduced with rAAV encoding HSA did not show either increased capillary formation or leukocyte recruitment (Fig. 3A and inset, Fig. 4A, E) .
Effects of combined expression of mHIF-1α with arteriogenic growth factors
Ang-1 has been shown to induce vascular maturation (7, 20) , and PDGF-B is known to recruit vascular pericytes and smooth muscle cells to newly formed capillaries (21) . We wanted to test these factors to see if they could further enhance the maturation and stability of the new vessels.
Page 4 of 16 (page number not for citation purposes)
Therefore, mTAs were transduced with rAAVs expressing mHIF-1α in combination with Ang-1 or PDGF-B. Immunohistochemistry of the muscles transduced with these combinations showed increased capillary proliferation and sprouting, as in the case of mHIF-1α alone (Fig. 4B, C) . In addition, in the muscles overexpressing HIF-1α together with PDGF-B, the number of pericytes was increased as visualized with the NG2 staining (see Fig. 4C ). On the other hand, staining for smooth muscle actin did not show increased proliferation of smooth muscle cells in the PDGF-B transduced muscles (data not shown). mHIF-1α, alone or in combination with Ang-1 or PDGF-B, was also analyzed in thick mTA sections where intact capillaries could be visualized (Fig.  4E-H) . In skeletal muscle, capillaries run longitudinally in parallel to the muscle fibers, as shown in the control-injected mTA (Fig. 4E) . However, capillary proliferation and sprouting, seen in the low-power immunostaining images (Fig. 4A-C) , was clearly evident in confocal microscopy of corresponding immunostainings (Fig. 4F, G, H) . These analyses showed numerous new capillaries inter-connecting in between the muscle fibers. The pattern obtained by mHIF-1α transduction resembled that reported for exercise-induced angiogenesis in muscles after physical training (22) .
Vascular permeability in mHIF-1α or VEGF overexpressing muscle
VEGF overexpression often results in leaky vessels as shown by previous pre-clinical animal studies (23) (24) (25) . However, such an outcome would not be acceptable for clinical gene therapy. The functional significance of the observed increase in capillary density was tested by measuring vascular leakage with Evans Blue dye as described in Materials and Methods. The results indicated that TAs overexpressing the two mouse VEGF isoforms displayed high vascular permeability; the VEGF 120 isoform especially induced very leaky vessels (Fig. 5) . The permeability was somewhat reduced when VEGF 120 was co-expressed together with Ang-1. Interestingly, in the mTAs overexpressing mHIF-1α, the leakiness was within the range seen in the rAAV-HSA transduced or native muscles and co-expression of Ang-1 or PDGF-B did not further decrease these values.
Improved vascular perfusion in muscles overexpressing mHIF-1α
To assess the functional significance of mHIF-1α overexpression, vascular perfusion in the transduced muscles was measured by Doppler ultrasound imaging. The imaging showed that perfusion in mHIF-1α overexpressing muscle was significantly enhanced in comparison to the muscles expressing control virus (Fig. 6) . mHIF-1α together with Ang-1 also improved perfusion, whereas PDGF-B together with mHIF-1α only showed control-levels of perfusion.
DISCUSSION
Pro-angiogenic gene therapy aims at relieving the symptoms of ischemia resulting from occluded arteries in an atherosclerotic heart or limb. This mode of therapy has been under active development for the past ten years, but as with most gene therapy applications, its translation into clinical use is still awaiting greater clinical trial success (26) . Despite the vast number of published studies on angiogenic growth factors applicable to pro-angiogenic gene therapy, open questions remain regarding many of the surprising discoveries in the field. Of equal importance for gene therapy is the mode of gene transfer. In the current study, we have addressed aspects of VEGF mediated angiogenesis that have remained unclear despite the fact that VEGF is the most thoroughly studied angiogenic growth factor. As the vector for gene transfer, we used rAAV,
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which in recent years has become acknowledged as one of the most promising tools for various gene therapy applications, including use in cardiovascular diseases (27) .
Expression of the VEGF 164 or VEGF 120 splice forms in the mouse TA muscle resulted in massive proliferation of endothelial cells without their assembly into new vascular structures. The species specificity of VEGF was evident from experiments, where the human counterpart VEGF 165 only led to a mild increase of endothelial cells. Our observations thus agree with previously published studies using mouse VEGF (28, 29) . As the species-matched VEGF seemed unsuitable for use as a single agent for gene therapy, we tested a stabilized form of HIF-1α for its potential to promote angiogenesis. However, our initial long-term experiments with the rAAV-mHIF-1α-VP16, which is expressed at very high levels due to the viral transactivation domain, led to a gradual loss of luciferase expression in the rAAV-mHIF-1α-VP16 co-injected muscles. This may result from apoptosis of the rAAV-mHIF-1α-VP16 overexpressing muscle fibers, which supports the findings of an apoptotic role of HIF-1α in certain situations (30) (31) (32) (33) . We therefor used a point mutated form of full-length HIF-1α without the viral transactivation domain, which showed normal expression during the whole duration of the experiment. In this construct, the two target residues subject to prolyl hydroxylation have also been mutated to Ala residues (8) . The mutant protein is, therefore, not subject to ubiquitin-mediated degradation and is stably expressed and active in normoxic conditions. Successful proangiogenic results with this vector underlie the importance of appropriately adjusting the levels of transgene expression in gene therapy applications.
One of the main targets of HIF-1α mediated gene induction is VEGF. HIF-1α is also known to activate transcription of several other angiogenic genes (34, 35) . In our earlier study we showed that acute or chronic ischemia in the lower limbs of human patients induced several genes of the angiogenic cascade, for example HIF-1α, VEGF, and VEGFR-2 (36) . Therefore, overexpression of mHIF-1α could be expected to augment an angiogenic response. Indeed, we could detect significantly enhanced capillary numbers and sprouting in mHIF-1α transduced muscle. Although this effect probably resulted from activity of mHIF-1α-induced mouse VEGF, the use of mHIF-1α instead of direct VEGF overexpression contributed to the more contained and native angiogenic phenotype observed. Our results in this study confirm those of Elson et al. (2001) , who reported that a stabilized HIF-1α has significantly increased potency over individually overexpressed VEGF in transgenic mouse skin (12) . Here our model demonstrates that the approach can also be applied to skeletal muscle using AAV gene delivery, and thus it represents one step further toward the goals of cardiovascular gene therapy. VEGF up-regulation by mHIF-1α is likely to be responsible for the recruitment of circulatory leukocytes to the sites of rAAV-mHIF-1α transduction. This effect was VEGF-specific and not induced by the viral vector, as it was not detected in rAAV-HSA transduced muscles. Importantly, the lack of vector-induced immune response by rAAV contrasts with the strong immune response and tissue damage observed when an adenovirus has been used in immunocompetent recipients (37, 38; Pajusola et al., unpublished data, 2004 ).
Angiogenesis and arteriogenesis are complex processes, which involve several different growth factors contributing to the distinct phases of the cascade that leads to the development of a functional vascular network. For example, Ang-1 has been observed to enhance the stability of newly formed endothelial capillaries and PDGF-B is known to stimulate proliferation of pericytes and smooth muscle cells incorporated into the vascular wall (7, 21) . Accordingly, recent pro-angiogenic studies have shown that application of a single factor such as VEGF does not necessarily result in the desired outcome. Many studies using VEGF as the sole angiogenic inducer have demonstrated defective connection of the newly proliferated capillaries to the existing vasculature. Alternatively, the VEGF induced vessels regressed soon after growth factor withdrawal (39) . Furthermore, VEGF overexpression can lead to severe edema due to the strong vascular permeability induced by this growth factor. For these reasons, and in order to obtain stable and functional neo-vessels, we tested Ang-1 and PDGF-B together with mHIF-1α. As functional tests, we assayed permeability and vascular perfusion in growth factor transduced muscles. Although we could detect a clear increase in the number of pericytes among the sprouting new capillaries in response to PDGF-B overexpression, the impact of Ang-1 and PDGF-B on vessel permeability or function was insignificant. Our results with the Evans Blue permeability assay confirmed previously published findings on VEGF induced vascular permeability. The VEGF 120 isoform induced stronger leakage of the dye to the extravascular space than VEGF 164 . Interestingly however, the muscles overexpressing the stabilized HIF-1α, either alone or in combination with Ang-1 or PDGF-B, showed only a little vascular leak. Finally, we measured the improvement of vascular perfusion, which is obviously a very important criterion for successful vascular therapy. Doppler ultrasound analysis showed that perfusion was significantly enhanced in the mHIF-1α and mHIF-1α plus Ang-1 expressing muscles. Co-expression with PDGF-B, however, decreased the perfusion to control levels.
The reasons why the individually tested arteriogenic growth factors could not further improve the performance of mHIF-1α in our experiments may be twofold: Firstly, HIF-1α is known to induce numerous genes, that are required for angiogenic response, including all the genes used in this study (35, 40) . Using HIF-1α for gene therapy, therefore, provides a variety of necessary factors for angiogenesis. Secondly, and maybe more importantly from a gene therapy point of view, the concentrations of individually overexpressed factors may have been too high locally for their appropriate function. The mHIF-1α could circumvent this problem by inducing the required growth factors endogenously. In conclusion, our experiments indicated that mHIF-1α is a potent angiogenic inducer and that it can create favorable conditions for pro-angiogenic therapy. The top priorities for our future studies will, therefore, include characterization of the effects of mHIF-1α in ischemic tissues in mice and in larger animals. 
